Invention Application
WO2017191300A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML)
审中-公开
用于治疗化疗敏感性急性髓细胞性白血病（AML）的药物组合物
- Patent Title: PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHEMORESISTANT ACUTE MYELOID LEUKEMIA (AML)
- Patent Title (中): 用于治疗化疗敏感性急性髓细胞性白血病（AML）的药物组合物
-
Application No.: PCT/EP2017/060756Application Date: 2017-05-05
-
Publication No.: WO2017191300A1Publication Date: 2017-11-09
- Inventor: SARRY, Jean-Emmanuel , RECHER, Christian , DE TONI-COSTES, Fabienne , AROUA, Nesrine
- Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ PAUL SABATIER TOULOUSE III , CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
- Applicant Address: 101, rue de Tolbiac 75013 Paris FR
- Assignee: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE),UNIVERSITÉ PAUL SABATIER TOULOUSE III,CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
- Current Assignee: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE),UNIVERSITÉ PAUL SABATIER TOULOUSE III,CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
- Current Assignee Address: 101, rue de Tolbiac 75013 Paris FR
- Agency: COLLIN, Matthieu
- Priority: EP16305531.2 20160506
- Main IPC: A61K45/06
- IPC: A61K45/06 ; A61K31/00 ; A61K31/663 ; A61K31/704 ; A61K31/7068 ; A61K33/24 ; A61P35/02
Abstract:
The present invention relates to pharmaceutical compositions for use in the treatment of chemoresistant acute myeloid leukemia (AML). The inventors have established a powerful preclinical model to screen in vivo responses to conventional genotoxics and to mimic the chemoresistance and minimal residual disease as observed in AML patients after chemotherapy. The inventors showed that cytarabine-resistance mechanism involves the CD39-dependent crosstalk between energetic niche and AML mitochondrial functions through CD39-P2Y13-cAMP-PKA signaling axis. In particular, the present invention relates to an inhibitor of the CD39-P2Y13-cAMP-PKA signaling axis for use in a method of treating chemoresistant acute myeloid leukemia (AML) in a patient in need thereof comprising administering to the patient a therapeutically effective amount of said inhibitor.
Information query
